This is read by an automated voice. Please report any issues or inconsistencies here. The leading cause of infant hospitalization, RSV can trigger severe pneumonia and lung infections. Health ...

Over the past year, some vaccine recommendations have changed. Respiratory virus season is upon the United States as the cold weather months set in, meaning cases of COVID-19, influenza and RSV are ...

The FDA approved clesrovimab (Enflonsia) to prevent lower respiratory tract disease from respiratory syncytial virus (RSV) in infants born during or entering their first RSV season, drugmaker Merck ...

A new Cochrane review demonstrates that vaccines for respiratory syncytial virus (RSV) are both safe and effective in protecting vulnerable groups that are most at risk of serious illness, including ...

This article is part of “Innovations In: RSV” an editorially independent special report that was produced with financial support from MSD, Sanofi and AstraZeneca. After my dad died, I assumed that ...

This article is part of “Innovations In: RSV,” an editorially independent special report that was produced with financial support from MSD, Sanofi and AstraZeneca. When Laura Ehrlich gave birth to her ...

A single RSV vaccine dose is proving to be a powerful shield for older adults, significantly reducing hospitalizations and severe illness over two consecutive RSV seasons. While protection is ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Researchers studied real-world data on the effectiveness ...

In 2022, approximately 90% of RSV-positive samples in Boston were RSV-A. In 2024, in the same city, more than 80% of positive swabs were RSV-B. To look for potential signs of disease transmission, the ...

For infants less than 8 months of age born during or entering their first RSV season and not otherwise protected through maternal vaccination, nirsevimab is considered the first-line recommended ...

Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections in infants and children younger than 2 years. The most severe and life-threatening cases typically affect ...

The U.S. Food and Drug Administration expanded its approval of Moderna's respiratory syncytial virus (RSV) vaccine on Thursday to include adults under the age of 60 at increased risk of the disease.